Experience in genetic testing of hypertrophic cardiomyopathy using nanopore DNA sequencing

Experience in genetic testing of hypertrophic cardiomyopathy using nanopore DNA sequencing

Aim. To investigate the application of the Oxford Nanopore Technologies’ third generation sequencing for the genetic testing of hypertrophic cardiomyopathy.Material and methods. The study involved 12 patients with hypertrophic cardiomyopathy aged 18 to 67 years (women, 9; men, 3). Using the PCR barc...

Descrición completa

Detalles Bibliográficos
Main Authors: R. R. Salakhov, M. V. Golubenko, E. N. Pavlukova, A. N. Kucher, N. P. Babushkina, N. R. Valiahmetov, A. V. Markov, E. O. Belyaeva, A. F. Kanev, M. S. Nazarenko
Formato: Artigo
Idioma:Russian
Publicado: «FIRMA «SILICEA» LLC 2021-11-01
Series:Российский кардиологический журнал
Subjects:
hypertrophic cardiomyopathy
monomolecular sequencing
oxford nanopore technology
myh7
mybpc3.
Acceso en liña:https://russjcardiol.elpub.ru/jour/article/view/4673

Internet

https://russjcardiol.elpub.ru/jour/article/view/4673

Títulos similares